Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Published by:
Stanford Business School (2012)
Version:
8 May 2012
Length:
11 pages
Data source:
Field research

Abstract

This is part of a case series. Yasuchika Hasegawa, president of Takeda Pharmaceutical Company, had a vision to make Takeda a top tier company in oncology by 2015. In 2008, Takeda acquired Millennium Pharmaceuticals, a respected oncology company with annual sales of $528 million in 2007 and a promising pipeline of new drugs. Hasegawa and Millennium CEO Deborah Dunsire believed that it was critical to convey a consistent vision for the future of Millennium within Takeda and help Millennium employees feel positive about the company’s future. Millennium would operate independently and become Takeda’s 'Center of Excellence in Oncology.' This case explores the steps that Hasegawa took to successfully integrate Millennium. His priorities centered on retaining Millennium talent and addressing the friction that arose from two very different corporate cultures. He also used the opportunity to transform Takeda’s risk averse culture into a more innovative and flexible one that would support Takeda becoming a truly global pharmaceutical company.

Topics

Mergers and Acquisitions (M&A); Growth strategy; Global business; Pharmaceuticals; Cultural clashes; Emerging markets; Business processes; Strategic planning

Access this item

casecent.re/p/111421
View our pricing guide
or to see prices.

Reviews & usage